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Fatigue in Older adults 
Postmyocardial infarction
Patricia Barton Crane1* , Jimmy T. Efird1 and Willie Mae Abel 2
1 College of Nursing, East Carolina University, Greenville, NC, USA, 2 Department of Nursing, University of North Carolina at 
Charlotte, Charlotte, NC, USA
Objective: The purpose of this study was to comprehensively examine putative factors 
that may independently contribute to fatigue and subsequent persistence of fatigue 
in elderly adults 6–8 months post-myocardial infarction (MI). Studies suggest cardiac 
function, comorbidities, daytime sleepiness, depression, anemia, interleukins, and social 
support are correlates of fatigue; however, no studies have systematically examined 
these factors 6 months post-MI in an aging population.
Methods: Study participants included 49 women and men (N = 98) ages 65–91 who 
were 6–8 months post-MI. Data collection included the demographic health status ques-
tionnaire (heart rate, blood pressure, body mass index, and medications), fatigue-related 
comorbidity scale, revised Piper fatigue scale, Epworth sleepiness scale, geriatric 
depression scale, social provisions scale, and venous blood tests (B-natriuretic peptide, 
hemoglobin, and interleukin-6).
results: Fatigue persisted after MI in 76% of older men and women with no difference by 
sex. Only depression scores (Ptrend = 0.0004) and mean arterial pressure (Ptrend = 0.015) 
were found to be linearly independent predictors for fatigue, controlling for age, Il-6 
levels, and body mass index.
conclusion: Post-MI depression and mean arterial blood pressure are important to 
assess when examining fatigue post-MI in older populations.
Keywords: fatigue, aging, myocardial infarction
inTrODUcTiOn
The majority of annual myocardial infarctions (MIs) occur in those aged 65 and older with approxi-
mately 29% being recurrent events (1). These high recurrence rates may be related to a lack of sec-
ondary prevention behaviors. One of the most effective secondary prevention behaviors after an MI 
is physical activity. However, fatigue is one of the most frequently reported barriers to participation 
in physical activity (2). Fatigue reported with an MI is greater than fatigue associated with arthritis, 
diabetes, lung disease, migraines, or hypertension (3) and is the most common symptom reported 
5 months after MI in both men and women (4). This is concerning because fatigue is associated with 
poorer cardiac outcomes, including increased cardiac readmissions and sudden cardiac death (5).
Fatigue, tiredness, and exhaustion are commonly used descriptors of loss of stamina related to 
physical, emotional, and cognitive activity and are similar to mood descriptors such as “sad” and 
“blue.” Just as when “sadness” becomes a consistent emotion that contributes to a clinical diagnosis 
of depression, fatigue that persists is a significant problem affecting behavior and quality of life. 
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Typically fatigue is viewed as a multidimensional symptom 
consisting of a physical/behavioral, perceptual (sensory or affect), 
and cognitive components (6).
Research on fatigue in a post-MI population has largely been 
limited to the near term occurrence (3–4 months) following the 
MI (7). However, fatigue assessed in this short period may be 
associated with physiological recovery (8) and thus may not be 
the same as persistent fatigue that affects participation in physical 
activity and other behaviors associated with secondary preven-
tion. Furthermore, studies on fatigue post-MI have included either 
small numbers of elderly adults or no elderly adults; therefore, we 
cannot translate the findings to elderly adults who have the great-
est incidence of MI and are at the highest risk for recurrent MI.
Measuring fatigue at least 6 months after MI is important to 
allow for (1) physiological recovery and myocardial tissue to repair, 
(2) completion of cardiac rehabilitation Phase II, (3) stabilization 
of a medication regimen, (4) stabilization of emotional distress 
and functional ability (9), and (5) accurate capture of fatigue and 
factors associated with fatigue that persists over time post-MI. 
While previous studies with MI and other clinical populations 
suggest that cardiac function (10), comorbidities (11), sleep 
(12), depression (12), anemia (13), interleukin 6 (IL-6) (11), and 
social support (14) are independently associated with fatigue, no 
studies have systematically examined these factors and fatigue 
post-MI. The study of these comorbidities is especially important 
for the elderly population who has the highest incidence of MI. 
Therefore, the purpose of this study was to comprehensively 
examine putative factors that may independently contribute to 
fatigue and subsequent persistence of fatigue in elderly adults 
6–8 months post-MI.
We hypothesized that older age, female sex, more comorbidi-
ties, β-blocker usage, lower heart rate, poorer cardiac function (as 
measured by higher B-natriuretic peptide, BNP), anemia, higher 
IL-6, greater daytime sleepiness, more depression, and lower 
social support would explain fatigue 6–8 months post-MI among 
elderly adults.
MaTerials anD MeThODs
setting and Participants
The setting was a large metropolitan health-care system serving 
patients in the mid-central region of North Carolina. Adults 
aged 65 and older who had been discharged with a diagnosis of 
acute MI [International Classification of Diseases (ICD)-9 codes 
410.1–410.9] were recruited for the study. Inclusion criteria were 
the verbal validation of an MI by each participant and the ability 
to speak English. Exclusion criteria were used to control for issues 
that might affect the independent variables or symptom recall and 
included the following: a memory deficit (recall), as identified by 
a score of 6 or above on the Abbreviated Mental Test (15), taking 
antidepressant medication for depression (depression), major 
surgery within the last 6  months (inflammation), or chemo-
therapy for cancer within the last 12  months (inflammation). 
The study was approved by the university and medical center’s 
institutional review boards, and informed consent was obtained 
from each participant.
Design and Procedure
We used a cross-sectional descriptive design to identify putative 
factors that independently contributed to fatigue and subsequent 
persistence of fatigue in the months following the occurrence of 
an MI. Potential participants who agreed to release their name and 
telephone number to a site collaborator from the medical center 
were contacted by telephone to further explain the study, answer 
any questions, confirm eligibility, and establish a time to collect 
data. Participants were met at their chosen location, and data were 
collected. The procedure for data collection included (a) complet-
ing the demographic health status (DHS) questionnaire, a form to 
gather data related to family history of heart disease, risk status, 
cardiac rehabilitation attendance, and other queries, including 
obtaining height and weight using a standardized scale, measur-
ing the pulse and blood pressure, querying the participant about 
comorbidities using the fatigue-related comorbidity scale, visually 
observing and validating with the participant that they were taking 
the medication as directed for the specified comorbidity, and docu-
menting all medications and dosages on the DHS questionnaire; 
(b) collecting a venous blood sample to measure BNP, hemoglobin 
(Hgb), and IL-6; and (c) completing the revised Piper fatigue scale 
(RPFS), the Epworth sleepiness scale (ESS), the geriatric depres-
sion scale (GDS), and the social provisions scale (SPS).
Measures
Demographic data were collected with a standard form. 
Additionally, time of data collection was recorded to examine the 
relationship of time of day to results. Comorbidities were meas-
ured by the fatigue-related comorbidity scale. This instrument 
was developed by the first author by adapting and combining 
the chronic disease score and the Charlson comorbidity index to 
obtain a comprehensive list of comorbidities. “The validity of a 
comorbidity index is assessed by how well the index predicts those 
outcomes …” (p. 892) (16). Comorbidity scores could range from 
0 to 67 with higher scores associated with higher comorbidities.
A sample of venous blood (10 cc of whole blood) was obtained 
using a 23-gauge needle and placed in standardized blood vials. 
One vial was centrifuged using a portable centrifuge, and the 
serum was extracted using a pipette and placed in the appropriate 
vial designated by the lab’s protocol.
Ventricular function was measured by the BNP level. BNP is 
more sensitive (90%) than clinical judgment (49%) in diagnos-
ing heart failure, with greater sensitivity than atrial natriuretic 
peptides in the elderly (17). BNP levels reflect both systolic and 
diastolic failure (18), and an increased BNP indicates reduced 
ventricular systolic and diastolic function. The BNP was meas-
ured using a venous sample and the ADVIA Centaur BNP assay. 
A receiver operator curve analysis indicated that the area under 
the curve for the ADVIA Centaur BNP assay is 0.919 with a 95% 
CI of 0.904–0.934 (19).
Anemia was determined by the Hgb lab value and recorded 
as a dichotomous variable. Using the criteria from the World 
Health Organization (20), Hgb levels below 12 g/dL in women 
and below 13 g/dL in men signified the presence of anemia. Hgb 
was measured using an automated cell counter of EDTA whole 
blood.
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IL-6 was measured using an IMMULITE Analyzer in EDTA 
plasma. A sample of 100 μL of serum was required, and the sample 
could be stored for 24 h at 2–8°C. This test has a 99% specificity, 
an analytical sensitivity of 5 pg/mL, and has reliability estimates 
of 0.994–0.998 (19).
The RPFS is a 27-item tool that measures four subjective 
dimensions of fatigue; it is one of the few fatigue tools that has 
been used with elderly adults (21). Prior to administering the 
RPFS, the participants were asked if they had experienced fatigue, 
tiredness, or exhaustion after their MI that differed from fatigue 
experienced prior to their MI. This question was to clarify per-
sistent fatigue post-MI from fatigue they would note as “normal” 
or “typical” fatigue. If they answered no to the question, which is 
their fatigue was the same or less than fatigue experienced prior 
to MI, they then received a 0 score on the RPFS. If they answered 
yes, they proceeded to complete the RPFS, and this fatigue was 
noted as “atypical” fatigue. The 22 items of the RPFS are on a 0–10 
scale. The total fatigue score is computed by summing all 22 items 
and can range from 0 to 220. Reliability and validity estimates 
are moderate to strong (22), and internal consistency reliability 
estimates are above 0.80 (6). In this study, the standardized alpha 
for the total instrument was 0.95.
Daytime sleepiness was measured using the ESS (23). This 
scale is composed of eight scenarios for which respondents rate 
the likelihood of falling asleep, from 0 = never doze to 3 = high 
chance of dozing, for a total possible score of 24. Higher scores 
indicate more daytime sleepiness. ESS scores are significantly 
associated (P < 0.01) with the multiple sleep latency test at night 
and with polysomnography (23). Test–retest reliability is reported 
at 0.82 (24), and Cronbach’s alpha was 0.78.
Depression was measured using the 15-item GDS (25). This 
scale was selected over the 5-item scale to better approximate 
a normal distribution and satisfy assumptions for statistical 
analyses (25). The 15-item scale contains statements to which 
respondents answer either “yes” or “no.” Five items are reversed; 
the “no” receives a point, and these items are added to the “yes” 
items of the other statements, with possible scores ranging from 
0 to 15. A cutoff-point score of 5–6 produced 85% sensitivity 
and 74% specificity in screening for depression (26). Internal 
consistency of 0.83 was found in a study of elderly adults (27). 
Cronbach’s alpha for this study was 0.81.
Perceived social support was measured using the SPS, a 24-item 
questionnaire developed (28) to assess the six provisions of social 
relationships described by Weiss: guidance (advice or informa-
tion), reliable alliance (assurance that others can be counted on 
in times of stress), reassurance of worth (recognition of one’s 
competence), attachment (emotional closeness), social integra-
tion (a sense of belonging to a group of friends), and opportunity 
for nurturance (providing assistance to others). Each provision is 
measured by four items: two that describe the presence and two 
that describe the absence of the provision. The instrument uses a 
4-point Likert-type scale (1 = strongly disagree and 4 = strongly 
agree) and contains both positive and negative scoring items to 
help control response patterns. Internal consistency ranges from 
0.85 to 0.92 (29). The coefficient alpha for this study was 0.90.
All forms and instruments were printed in 14-point font 
on white paper to ensure ease of reading. Participants were 
provided the opportunity to read or have the information read 
to them. The average time to complete data collection was 
90 min, and participants were offered breaks throughout. Each 
participant received a $20 gift certificate upon completion of 
data collection.
statistical analyses
Categorical variables were expressed as frequency and percent-
age, whereas continuous variables were reported as median 
(Md) and interquartile range (IQR). We also plotted the military 
time of the interview against the overall fatigue score (the over-
all score for each subscale) to identify the magnitude of fatigue 
in relation to the timing of the interview. Because no pattern 
was observed, the timing of the interview was not included as a 
covariate in the analysis.
Fatigue was considered as an overall score. To analyze the 
outcome response of fatigue, we categorized the sample into those 
reporting post-MI fatigue that differed from fatigue prior to their 
MI and those reporting no difference in fatigue post-MI.
A Fisher’s exact test was used to determine if the proportion of 
women with fatigue was greater than the proportion of men with 
fatigue. The Deuchler–Wilcoxon exact procedure for continuous 
variables was used to compare the Mds of men and women on the 
overall fatigue scale. In addition, we used graphical assessments 
to visually inspect significant differences in the distributions of 
fatigue scores for men and women.
A Poisson regression model was used to compute adjusted 
relative risks (RR) for fatigue. This analysis determines the contri-
bution each independent variable makes alone and in combina-
tion with other independent variables in predicting the outcome 
response, the presence of fatigue. Model fit was assessed using 
deviance-based diagnostic plots. To control the influence of outli-
ers, each continuous predictor variable was quartiled from low to 
high values, with the first quartile serving as the reference point 
(1.0). Each of the following three quartiles was then compared 
to the referent. For example, if quartile 3 had an RR of 1.6, those 
in this quartile were 60% more likely to have the variable than 
the referent. Tests for trend, to denote an increased or decreased 
risk associated with a linear change in the predictor variables, 
are presented where appropriate, and P-values were computed 
using a likelihood ratio procedure. We computed 95% confidence 
intervals for model parameters using robust variance “sandwich” 
estimates. Variables included in the multivariable model were 
those found to be statistically significant in univariable analyses 
(e.g., confidence intervals did not include unity in at least one 
category) or displayed a significant linear trend. The pairwise 
addition of other variables did not substantively change the 
results. P-values <0.05 were considered statistically significant. 
Results were not adjusted for multiplicity in this pilot analysis. 
SAS Version 9.3 (Cary, NC, USA) was used for all analyses.
resUlTs
A sample of 49 women and 49 men (N = 98) ranging in age from 
65 to 91 (Md = 76, IQR = 10) and 6–8 months post-MI partici-
pated in this study. Most were white (84%), married (51%), had 
a high school education or less (61%), and reported an average 
TaBle 1 | sample characteristics according to the presence of fatigue 
after myocardial infarction.
characteristic Fatigue 
(N = 74)
n (%)
Median [iQr]
no fatigue 
(N = 24)
n (%)
Median [iQr]
P-valuea
Demographics
Age (years) 77 [11] 73 (7) 0.046
Female 40 (54) 9 (38) 0.24
High school or greater 50 (68) 19 (79) 0.32
Income ≥ $20,000 44 (59) 18 (75) 0.23
Married 37 (50) 13 (54) 0.82
White 61 (82) 21 (88) 0.75
Medical history/laboratory measurements
B-natriuretic peptide (pg/mL) 118 [152] 118 [235] 1.0
β-blocker use 64 (86) 20 (83) 0.74
Body mass index (kg/m2) 28 [8] 29 [6] 0.29
Heart rate (beats/min) 64 [13] 63 [13] 0.85
Hemoglobin (g/dL) 13 [2] 13 [1] 0.21
Interleukin-6 (μg/dL) 5 [3] 4 [4] 0.034
Mean arterial pressure 
(mmHg)b
82 [17] 92 [16] 0.0062
Measurement scales/scores
Comorbidities score 10 [5] 10 [5] 0.58
Epworth sleepiness scale 6 [7] 6 [5] 0.55
Geriatric depression scale 2 [3] 1 [1] 0.0003
Social provisions scale 35 [17] 31[11] 0.16
aP-values computed using Fisher’s exact test for binary variables and Deuchler–
Wilcoxon’s exact test for continuous variables.
bComputed as [(2 × diastolic blood pressure) + systolic blood pressure]/3.
4
Crane et al. Fatigue in Elderly Postmyocardial Infarction
Frontiers in Public Health | www.frontiersin.org April 2016 | Volume 4 | Article 55
DiscUssiOn
Results of this study demonstrate that fatigue persists 6–8 months 
after an MI in the majority (76%) of elderly men and women. 
These results are considerably higher than the 33% of elderly 
adults from the community who reported fatigue lasting 
1–12 months (21). This is concerning since not only has fatigue 
been reported to decrease participation in physical activity (21, 
30), but this symptom can affect the quality of life of persons post-
MI (21) and is associated with poorer cardiovascular outcomes 
(5). Comparing levels of fatigue with other studies is difficult 
because of the various measures used in other studies, such as the 
SF-36 vitality scores (31), a visual analog scale (31), a symptom 
checklist (32), or a question related to the presence of fatigue 
(33). At the time of this study, the National Institutes of Health’s 
Patient-Reported Outcomes Measurement Information System 
(PROMIS) measure for fatigue was not available, and using this 
standardized measure may yield comparable results across time 
and populations. Because fatigue is subjective, identification of 
only the presence of this symptom may be clinically important 
when addressing barriers to secondary prevention or symptoms 
affecting the quality of life.
There was no significant difference in the prevalence of fatigue 
or the fatigue scores between men and women. While these results 
are consistent with another study (34), a different study found 
that women had more fatigue than men; however, they measured 
vital exhaustion, a concept that includes fatigue or exhaustion 
but also includes irritability and demoralization (35). Therefore, 
these differences noted in men and women may or may not have 
been related to fatigue, but rather to irritability or demoralization. 
Results from this study indicate that elderly adults, regardless of 
sex, have fatigue post-MI and should be targeted for interventions.
In multivariable analysis, only depression scores and MAP 
were significantly different from those persons reporting no 
fatigue after MI. Post-MI depression is important because those 
identified as having mild to major depression report a lower 
adherence to risk reduction behaviors, such as regular exercise 
(36), and they have higher mortality. While depression is 
prevalent in older persons with cardiovascular disease and those 
post-MI, in this study, the proportion of depression is similar to 
the prevalence of depression in an elderly adult population (37) 
and less than the prevalence of depression in cardiac populations 
(38). These differing results may be related to the timing of meas-
urement. Many studies examining depression post-MI measured 
depression within the first 4 months after MI (39). However, a 
synthesis of the literature noted that depression does not stabilize 
until 6  months (9). Therefore, the lower percentage of persons 
who had scores that indicated depression in this study may be 
related to measuring depression 6–8 months post-MI. Despite the 
low percentage of persons with scores screening for depression, 
this variable was the strongest predictor of fatigue that persists 
post-MI. Because fatigue may also affect depression, further 
examination of depression and fatigue is warranted to develop 
interventions to affect fatigue post-MI.
The other significant variables contributing to fatigue 
6–8 months post-MI in the univariable analyses were IL-6 and 
household income less than $40,000 (57%). The majority (72%) 
of participants reported 4–7 comorbidities. The Md comorbidity 
score for the total sample was 11 (IQR = 5). The Md systolic blood 
pressure for those who indicated fatigue was 120 (IQR = 22) and 
for not fatigued was 135 (IQR = 41). The Md diastolic blood pres-
sure for those indicating fatigue was 64 (IQR = 12) and for those 
with no fatigue was 70 (IQR = 13). See Table 1 for descriptions 
of the demographics and predictor variables by fatigue presence.
A total of 74 (76%) participants reported fatigue that was 
different than fatigue prior to their MI. The average fatigue 
score for each subscale was (a) function (Md = 13, IQR = 19); 
(b) behavioral/severity RPFS (Md = 22, IQR = 25); (c) affective 
meaning RPFS (Md = 20, IQR = 21); (d) sensory RPFS (Md = 21, 
IQR = 17); and (e) cognitive/mood RPFS (Md = 18, IQR = 19). 
Fisher’s exact test indicated no differences in the proportion 
of women and men reported fatigue after MI (P  =  0.152). 
Additionally, women did not have significantly higher levels of 
fatigue than men (U = 2398.5; P = 0.85).
A statistically significant unadjusted linear trend was observed 
for IL-6, mean arterial blood pressure (MAP), GDS, and age 
(Table 2). Compared with underweight participants, those who 
were normal, pre-obese, or obese were significantly more likely to 
report fatigue; however, the effect was not linear. Only depression 
scores (Ptrend = 0.0004) and mean arterial pressure (Ptrend = 0.015) 
were found to be linearly independent predictors for fatigue, 
controlling for age, Il-6 levels, and body mass index.
TaBle 2 | Univariable and multivariable factors contributing to fatigue.
characteristics Univariable
rr (95% ci)
Multivariable
rr (95% ci)
age (years)
Q1 (≤70) 1.0 referent 1.0 referent
Q2 (>71–76) 1.1 (0.76–1.5) 1.2 (0.82–1.6)
Q3 (>76–81) 1.1 (0.76–1.5) 1.2 (0.89–1.6)
Q4 (>81) 1.4 (1.1–1.9)† 1.2 (0.95–1.6)¥
Body mass index (kg/m2)
Q1 Underweight 1.0 referent 1.0 referent
Q2 Normal 0.84 (0.71–0.994) 0.88 (0.57–1.3)
Q3 Pre-obese 0.73 (0.60–0.89) 0.83 (0.52–1.3)
Q4 Obese 0.71 (0.57–0.88)¥ 0.81 (0.51–1.3)¥
geriatric depression scale
Q1 (≤1) 1.0 referent 1.0 referent
Q2 (>1–2) 1.5 (1.1–2.0) 1.5 (1.1–2.0)
Q3 (>2–4) 1.4 (1.01–1.9) 1.5 (1.1–2.1)
Q4 (>4) 1.7 (1.3–2.2)§ 1.6 (1.2–2.0)§
interleukin-6 (μg/dl)
Q1 (≤3) 1.0 Referent 1.0 Referent
Q2 (>3–5) 1.2 (0.87–1.8) 1.1 (0.81–1.6)
Q3 (>5–7) 1.3 (0.90–1.8) 1.2 (0.89–1.6)
Q4 (>7) 1.4 (1.01–1.9)† 1.1 (0.81–1.5)¥
Mean arterial pressure (mmhg)
Q1 (≤77) 1.0 referent 1.0 referent
Q2 (>77–85) 0.92 (0.73–1.2) 0.95 (0.72–1.3)
Q3 (>85–94) 0.88 (0.69–1.1) 0.95 (0.71–1.3)
Q4 (>94) 0.56 (0.36–0.87)‡ 0.62 (0.40–0.96)†
B-natriuretic peptide (pg/ml)
Q1 (≤74) 1.0 Referent –a
Q2 (>74–118) 1.1 (0.79–1.5)
Q3 (>118–251) 1.0 (0.74–1.4)
Q4 (>251) 1.0 (0.74–1.4)¥
β-Blockers
No 1.0 referent –a
Yes 1.1 (0.75–1.5)
comorbidities score
Q1 (≤8) 1.0 referent –a
Q2 (>8–10) 1.1 (0.83–1.5)
Q3 (>10–13) 0.95 (0.67–1.4)
Q4 (>13) 1.2 (0.88–1.6)¥
epworth sleepiness scale
Q1 (≤3) 1.0 referent –a
Q2 (>3–6) 0.99 (0.71–1.4)
Q3 (>6–9) 1.1 (0.76–1.5)
Q4 (>9) 1.1 (0.85–1.5)¥
heart rate (beats/min)
Q1 (≤57) 1.0 referent –a
Q2 (>57–64) 0.90 (0.66–1.2)
Q3 (>64–70) 1.0 (0.76–1.4)
Q4 (>70) 0.94 (0.69–1.4)¥
hemoglobin (g/dl)
Q1 (≤12) 1.0 referent –a
Q2 (>12–13) 0.97 (0.74–1.3)
Q3 (>13–14) 0.79 (0.56–1.1)
Q4 (>14) 0.95 (0.71–1.3)¥
(Continued)
characteristics Univariable
rr (95% ci)
Multivariable
rr (95% ci)
Married
No 1.0 referent –a
Yes 1.0 (0.83–1.3)
race
Black 1.0 referent –a
White 1.1 (0.84–1.4)
sex
Male 1.0 referent –a
Female 0.85 (0.68–1.07)
social provision scale
Q1 (≤28) 1.0 referent –a
Q2 (>28–34) 0.94 (0.65–1.4)
Q3 (>34–43) 1.0 (0.75–1.4)
Q4 (>43) 1.2 (0.91–1.6)¥
Likelihood ratio trend test (¥P > 0.05, †P ≤ 0.05, ‡P ≤ 0.01, and §P ≤ 0.001).
CI, confidence interval; RR, relative risk.
aNot included in multivariable model.
TaBle 2 | continued
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age. Proinflammatory cytokines increase with age (40), and high 
levels are associated with sickness behavior: fatigue, fever, and 
general malaise. Increased levels of cytokines, especially IL-6 
and tumor necrosis factor alpha (TNFα), are also associated with 
frailty (41), decreased muscle endurance (42), and heart failure 
(43). Although cytokines have been associated with fatigue in 
those with cancer and diabetes (44, 45), no studies were found 
that examined IL-6 as an explanatory factor for persistent fatigue 
after MI. Because increases in inflammatory markers are associ-
ated with increased risk of cardiovascular disease (43), expanding 
the study of cytokines to understand the relationship of cytokines 
to persistent fatigue after MI is important.
Comorbidities, such as rheumatoid disease (46) and cancer (30), 
have been associated with fatigue (3), and comorbid conditions 
increase with age (3). Those with cardiovascular disease, especially 
elderly adults (37), have a higher number of comorbidities, includ-
ing diabetes, hypertension, hypercholesterolemia, and obesity. 
Results of this study, in contrast to some reports in the literature, did 
not observe an association between comorbidities and fatigue (3, 
44). Further studies are needed to facilitate understanding of how 
comorbid conditions differentially contribute to fatigue post-MI.
Consistent with some (12, 45), but not another study (47), 
social support was not an important variable in explaining fatigue 
in the current analysis. The relationship of social support to 
fatigue is unclear, and continued research is needed to clarify the 
types of social support, if any, which potentially impact fatigue 
post-MI. Also, daytime sleepiness, though significant in another 
study (12), was not significant in this study. Further research is 
needed to clarify the relationship of sleep and fatigue post-MI.
Cardiac function (BNP and heart rate) was not associated with 
persistent fatigue in elderly adults post-MI, while MAP was a sig-
nificant predictor. While fatigue is a common symptom reported 
in heart failure (10), BNP, an indicator of failure (18), was not 
associated with fatigue. Heart rate and cardiac contractility are 
6Crane et al. Fatigue in Elderly Postmyocardial Infarction
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used to compute cardiac output. The independent contribution 
of contractility and heart rate did not predict fatigue, but the out-
come of a decreased cardiac output, decreased MAP, did predict 
fatigue. Because the MAP is a simple, non-invasive measure and 
lower MAP is a side effect of post-MI pharmacological therapy, 
including this measure when examining fatigue post-MI is 
warranted.
One of the limitations of this preliminary analysis was the 
sample size of 98, but this is one of the only studies to date com-
prehensively addressing correlates to fatigue in an aging post-MI 
population. This study was conducted at a single medical center, 
which makes it difficult to generalize the study findings to other 
centers that may not have similar patient profiles. A cross-sectional 
analysis only measures the variables at one point in time; therefore, 
patterns of associations can neither be determined nor could we 
examine differences in fatigue at each month. Using a self-report 
measure of fatigue may have biased the findings. Because only 
those persons who agreed to release their names to the research 
team were contacted, those who did not choose to participate in 
the research could have reported more or less fatigue. However, 
those who did not participate did not substantively differ from the 
participants with respect to age and sex.
cOnclUsiOn
The results of this pilot study provide important information 
to understand the prevalence of fatigue and factors associated 
with the persistence of fatigue post-MI. While these results have 
important implications for practice, this model should be tested 
in a larger sample. Further studies are needed to better understand 
the persistence of fatigue after MI over time in elderly adults and 
to develop interventions targeted at decreasing or eliminating 
fatigue.
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